BCMA x CD16a

(RG6296) 

Hematology

Phase I

A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

NCT04434469